Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics bolsters board

Silence Therapeutics has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments
Silence Therapeutics bolsters board
Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International...

Silence Therapeutics (LON:SLN) has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments.

Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International and was chairman, chief executive and president of previously listed Aurora Biosciences, which was acquired by Vertex Pharmaceuticals (NASDAQ:VRTX) in 2001.

He has held various positions in public and private life science companies in the US and Europe and is a partner of Forward Ventures, a biopharmaceutical venture capital fund.

Ali Mortazavi, the chief executive of Silence Therapeutics, said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

Shares were unchanged at 137.875p.

Giles_55af4ddca6481.jpg
Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

Related Articles

genomics.jpg
January 20 2016
“Redx Pharma’s in-licensed and internally generated pipeline of proprietary drug candidates targeting significant unmet medical needs, particularly in the fields of infection and oncology, offers unique exposure to a number of exciting early-stage opportunities, in our view,” said Shore Capital analyst Dr Tara Raveendran.
CancerHeadline.jpg
February 24 2016
"We are swiftly moving towards our goal of becoming a clinical-stage development company," said CEO, Dr Tim Mitchell
Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.